Tonghua Dongbao's first three generations of insulin glargine obtained clinical approval within months
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the information on June 3 on the website of the State Food and Drug Administration (CFDA), the third-generation insulin glargine bulk drug and preparation insulin glargine injection that Tonghua Dongbao applied for clinical application has now become "under approval" If there is no accident, the company is expected to obtain the clinical approval document within the month At present, Tonghua Dongbao is mainly engaged in the production of second-generation insulin The clinical approval of insulin glargine will be the first three generation insulin approval obtained by the company Tonghua Dongbao executives have previously said that the product is expected to be approved in the first half of the year The company has already found a clinical research hospital After the clinical approval of insulin glargine is issued, it will enter the clinical research immediately It is expected to complete the clinical research in the middle of next year and then apply for production Insulin glargine is an insulin analogue, commonly known as "the third generation insulin" The third generation insulin products have been gradually accepted by patients and doctors because of shielding the shortcomings of the second generation products, effectively shortening the treatment time, and good pharmaceutical performance, and become the main drug in the urban insulin market At present, Tonghua Dongbao's second-generation insulin market is mature and competitive in China
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
